RUBY Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Rubius Therapeutics Share Price & Price History
Current Price: $0.06
Price Change: +0.30 (1.20%)
As of 12/29/2023 01:00 AM ET
Rubius Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/24/2023 | Dannielle Appelhans | CEO | Sell | 10,385 | $0.13 | $1,350.05 | | |
Rubius Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/14/2022 | Abbot Financial Management Inc. | 452,345 | $0.20M | 0.1% | -67.9% | 0.501% |  |
| 10/27/2022 | Baillie Gifford & Co. | 4,853,773 | $2.11M | 0.0% | -1.1% | 5.372% |  |
| 8/8/2022 | State of Michigan Retirement System | 657,738 | $0.56M | 0.0% | +2.8% | 0.729% |  |
| 8/5/2022 | Connor Clark & Lunn Investment Management Ltd. | 353,813 | $0.30M | 0.0% | +521.5% | 0.392% |  |
| 5/16/2022 | Maven Securities LTD | 86,238 | $0.48M | 0.0% | N/A | 0.096% |  |
| 5/12/2022 | Connor Clark & Lunn Investment Management Ltd. | 56,927 | $0.31M | 0.0% | N/A | 0.063% |  |
| 5/11/2022 | JPMorgan Chase & Co. | 3,064,499 | $16.89M | 0.0% | -3.1% | 3.398% |  |
| 5/9/2022 | Qube Research & Technologies Ltd | 58,414 | $0.32M | 0.0% | +84.9% | 0.065% |  |
| 5/6/2022 | Los Angeles Capital Management LLC | 57,680 | $0.32M | 0.0% | N/A | 0.064% |  |
| 5/6/2022 | IndexIQ Advisors LLC | 79,691 | $0.44M | 0.0% | N/A | 0.088% |  |
| 5/5/2022 | Baillie Gifford & Co. | 4,907,471 | $27.04M | 0.0% | -0.5% | 5.441% |  |
| 5/4/2022 | State of Michigan Retirement System | 640,000 | $3.53M | 0.0% | +88.2% | 0.710% |  |
| 5/4/2022 | Victory Capital Management Inc. | 2,932,248 | $16.16M | 0.0% | +20.0% | 3.251% |  |
| 4/29/2022 | Nisa Investment Advisors LLC | 41,900 | $0.23M | 0.0% | +5,137.5% | 0.046% |  |
| 2/22/2022 | Byrne Asset Management LLC | 3,810 | $37K | 0.0% | N/A | 0.004% |  |
| 2/15/2022 | Capital World Investors | 2,751,000 | $26.63M | 0.0% | +3.8% | 3.061% |  |
| 2/14/2022 | Lombard Odier Asset Management Switzerland SA | 267,653 | $2.59M | 0.2% | +9.2% | 0.298% |  |
| 2/14/2022 | Virtus ETF Advisers LLC | 12,773 | $0.12M | 0.0% | +70.8% | 0.014% |  |
| 2/14/2022 | ARCH Venture Management LLC | 349,908 | $3.39M | 0.4% | N/A | 0.389% |  |
| 2/11/2022 | Ensign Peak Advisors Inc | 10,560 | $0.10M | 0.0% | N/A | 0.012% |  |
| 2/10/2022 | JPMorgan Chase & Co. | 3,161,516 | $30.60M | 0.0% | +28.9% | 3.518% |  |
| 2/10/2022 | Qube Research & Technologies Ltd | 31,587 | $0.31M | 0.0% | N/A | 0.035% |  |
| 2/10/2022 | Rafferty Asset Management LLC | 119,669 | $1.16M | 0.0% | +39.0% | 0.133% |  |
| 2/10/2022 | Citigroup Inc. | 137,351 | $1.33M | 0.0% | +44.7% | 0.153% |  |
| 2/10/2022 | TD Asset Management Inc. | 64,710 | $0.63M | 0.0% | N/A | 0.072% |  |
| 2/9/2022 | Principal Financial Group Inc. | 10,749 | $0.10M | 0.0% | -33.4% | 0.012% |  |
| 2/9/2022 | BNP Paribas Arbitrage SA | 16,787 | $0.16M | 0.0% | +97.5% | 0.019% |  |
| 2/8/2022 | Handelsbanken Fonder AB | 14,900 | $0.14M | 0.0% | +22.1% | 0.017% |  |
| 2/8/2022 | ProShare Advisors LLC | 22,695 | $0.22M | 0.0% | -9.5% | 0.025% |  |
| 2/8/2022 | Northern Trust Corp | 435,677 | $4.22M | 0.0% | -2.9% | 0.485% |  |
| 2/7/2022 | Victory Capital Management Inc. | 2,443,000 | $23.65M | 0.0% | +34.9% | 2.718% |  |
| 2/7/2022 | SG Americas Securities LLC | 30,096 | $0.29M | 0.0% | -33.8% | 0.033% |  |
| 2/7/2022 | Mitsubishi UFJ Kokusai Asset Management Co. Ltd. | 21,305 | $0.22M | 0.0% | +79.8% | 0.024% |  |
| 2/1/2022 | Qube Research & Technologies Ltd | 31,587 | $0.31M | 0.0% | N/A | 0.035% |  |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 44,915 | $0.43M | 0.0% | N/A | 0.050% |  |
| 1/20/2022 | Baillie Gifford & Co. | 4,930,859 | $47.73M | 0.0% | +5.0% | 5.487% |  |
| 12/14/2021 | UBS Asset Management Americas Inc. | 32,298 | $0.58M | 0.0% | -20.4% | 0.036% |  |
| 11/16/2021 | Thrivent Financial for Lutherans | 40,782 | $0.73M | 0.0% | +173.9% | 0.045% |  |
| 11/16/2021 | Two Sigma Advisers LP | 143,300 | $2.56M | 0.0% | +345.0% | 0.159% |  |
| 11/16/2021 | Two Sigma Investments LP | 246,566 | $4.41M | 0.0% | +65.9% | 0.274% |  |
| 11/15/2021 | California State Teachers Retirement System | 57,795 | $1.03M | 0.0% | -7.0% | 0.064% |  |
| 11/12/2021 | Renaissance Technologies LLC | 20,500 | $0.37M | 0.0% | N/A | 0.023% |  |
| 11/12/2021 | Credit Suisse AG | 25,783 | $0.46M | 0.0% | +6.4% | 0.029% |  |
Data available starting January 2016
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Read More on Rubius Therapeutics
Volume
755,858 shs
Average Volume
1,154,788 shs
Market Capitalization
$5.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.59